Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure

Emergent BioSoultions has been awarded another large contract, their fifth this year, worth $63 million to develop an antidote spray device for the treatment of known or suspected acute cyanide poisoning.

This single-use intranasal spray device will deliver a stabilized form of isoamyl nitrite (SIAN) and is intended for use by first responders and medical personnel following a cyanide incident.

“Emergent has a successful history of developing medical countermeasures that address the U.S. government’s top priority public health threats,” said Sean Kirk, senior vice president, manufacturing operations and interim head, devices business unit at Emergent BioSolutions. “We are committed to fulfilling BARDA’s requirements for an easily-administered treatment for acute cyanide poisoning, in collaboration with Southwest Research Institute. The development of the intranasal SIAN device will expand the company’s portfolio of novel devices to combat chemical threats. We are excited about the potential of this product candidate to meet the needs of both the government and commercial markets.\"

The contract is for a period of five years and will involve collaboration with Southwest Research Institute in order to advance the development of SIAN towards licensure.

Emergent BioSoultions has been awarded another large contract, their fifth this year, worth $63 million to develop an antidote spray device for the treatment of known or suspected acute cyanide poisoning.
This single-use intranasal spray device will deliver a stabilized form of isoamyl nitrite (SIAN) and is intended for use by first responders and medical personnel following a cyanide incident.
“Emergent has a successful history of developing medical countermeasures that address the U.S. government’s top priority public health threats,” said Sean Kirk, senior vice president, manufacturing operations and interim head, devices business unit at Emergent BioSolutions. “We are committed to fulfilling BARDA’s requirements for an easily-administered treatment for acute cyanide poisoning, in collaboration with Southwest Research Institute. The development of the intranasal SIAN device will expand the company’s portfolio of novel devices to combat chemical threats. We are excited about the potential of this product candidate to meet the needs of both the government and commercial markets.\"
The contract is for a period of five years and will involve collaboration with Southwest Research Institute in order to advance the development of SIAN towards licensure.

Our Current Sponsors

  • Flir
  • BioFire Defense
  • Federal Resources
  • Cristanini
  • Airboss
  • Flir
  • Argon
  • 908 Devices
  • Avon
  • Battelle
  • Flir
  • Bw Tek
  • CQC
  • Decon Seven Systems
  • DQE
  • Flir
  • Dxterity
  • First Line Technology
  • Futurtech
  • Metrohm Raman
  • Flir
  • NBC sys
  • Proengin
  • Qinetiq
  • Tex Shield
  • Flir
  • Wl Gore
  • ADS, Inc.
  • Rigaku Analytical Devices
  • Paul Boye Technologies
  • Flir
  • Observis
  • Zeteo Tech
  • Bertin Instruments
  • ECOTEST